Novartis

Latest stories

3h
Japan Today
Your inhaler's watching you: Drugmakers race for smart devices ‹ Japan Todayto governments and insurers, though they need to tread carefully on data privac
Your inhaler's watching you: Drugmakers race for smart devices ‹ Japan Today
Japan Today / Posted 3 hours ago
to governments and insurers, though they need to tread carefully on data privacy. GlaxoSmithKline, AstraZeneca and Novartis are all chasing the opportunity via deals with device firms including U.S.-based Propeller Health and... Read more
9h
The Toledo Blade
Medicare safeguard overwhelmed by pricey drugstop ten pricey medications, with more than $1 billion spent in 2015. That was a
Medicare safeguard overwhelmed by pricey drugs
The Toledo Blade / Posted 9 hours ago
top ten pricey medications, with more than $1 billion spent in 2015. That was a 54-percent increase from 2013. Drugmaker Novartis has been criticized for repeatedly hiking the price of Gleevec. — Catastrophic spending accounts for a fast-growing... Read more
8 related stories
11h
WDIO Duluth
Medicare Safeguard Overwhelmed by Pricey Drugstop ten pricey medications, with more than $1 billion spent in 2015. That was a
Medicare Safeguard Overwhelmed by Pricey Drugs
WDIO Duluth / Posted 11 hours ago
top ten pricey medications, with more than $1 billion spent in 2015. That was a 54-percent increase from 2013. Drugmaker Novartis has been criticized for repeatedly hiking the price of Gleevec. Catastrophic spending accounts for a fast-growing... Read more
5 related stories
13h
The Economic Times
Medicare safeguard overwhelmed by pricey drugstop ten pricey medications, with more than $1 billion spent in 2015. That was a
Medicare safeguard overwhelmed by pricey drugs
The Economic Times / Posted 13 hours ago
top ten pricey medications, with more than $1 billion spent in 2015. That was a 54-per cent increase from 2013. Drugmaker Novartis has been criticized for repeatedly hiking the price of Gleevec. _ Catastrophic spending accounts for a fast-growing... Read more
5 related stories
13h
Salon.com
AP Exclusive: Medicare safeguard overwhelmed by pricey drugstop ten pricey medications, with more than $1 billion spent in 2015. That was a
AP Exclusive: Medicare safeguard overwhelmed by pricey drugs
Salon.com / Posted 13 hours ago
top ten pricey medications, with more than $1 billion spent in 2015. That was a 54-percent increase from 2013. Drugmaker Novartis has been criticized for repeatedly hiking the price of Gleevec. — Catastrophic spending accounts for a fast-growing... Read more
8 related stories
13h
Daily Herald
AP Exclusive: Medicare safeguard overwhelmed by pricey drugstop ten pricey medications, with more than $1 billion spent in 2015. That was a
AP Exclusive: Medicare safeguard overwhelmed by pricey drugs
Daily Herald / Posted 13 hours ago
top ten pricey medications, with more than $1 billion spent in 2015. That was a 54-percent increase from 2013. Drugmaker Novartis has been criticized for repeatedly hiking the price of Gleevec. - Catastrophic spending accounts for a fast-growing... Read more
5 related stories
21h
Daily Record
Land Conservancy finds partners to make parks bettercorporations including AT&T, Bayer, BASF, Chubb Insurance, The Daily Record, Gl
Land Conservancy finds partners to make parks better
Daily Record / Posted 21 hours ago
corporations including AT&T, Bayer, BASF, Chubb Insurance, The Daily Record, GlaxoSmithKline, Investors Bank, JCP&L, Mars, Novartis, Pfizer, PSE&G, Prudential, Starbucks, Toyota/Lexus, Walmart and UPS have participated. “The corporations have been... Read more
21h
heraldscotland
Revealed: Scots doctors pocket millions from Big Pharma in just one yearBritish-Swedish multinational, doled out 254 TOVs totalling nearly £325,000. Gl
Revealed: Scots doctors pocket millions from Big Pharma in just one year
heraldscotland / Posted 21 hours ago
British-Swedish multinational, doled out 254 TOVs totalling nearly £325,000. GlaxoSmithKline is listed as making £255,000 worth of TOVs. Swiss giant Novartis registered 203 payments that were worth around £353,000. Pfizer made nearly £374,000 of TO... Read more
1d
heraldscotland
Revealed: Scots doctors pocket £4.5m from Big Pharma in just one yearBritish-Swedish multinational, doled out 254 TOVs totalling nearly £325,000. Gl
Revealed: Scots doctors pocket £4.5m from Big Pharma in just one year
heraldscotland / Posted yesterday
British-Swedish multinational, doled out 254 TOVs totalling nearly £325,000. GlaxoSmithKline is listed as making £255,000 worth of TOVs. Swiss giant Novartis registered 203 payments that were worth around £353,000. Pfizer made nearly £374,000 of TO... Read more
2d
Fortune
The Radical Experiment That’s Changing the Way Big Pharma Innovatesyear while the company established a proof-of-concept and pitched funders. Blad
The Radical Experiment That’s Changing the Way Big Pharma Innovates
Fortune / Posted 2 days ago
year while the company established a proof-of-concept and pitched funders. Blade’s investors include three J&J competitors Novartis, Pfizer, and Bristol Myers Squibb but Robbins heaps singular praise on J&J’s innovation strategy, which she... Read more
2d
Business Wire
Global $35 Billion Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel BiologicsAnalysis by Company 6.1.1 Pfizer - Will a Patent Cliff Be Avoided Following th
Global $35 Billion Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics
Business Wire / Posted 2 days ago
Analysis by Company 6.1.1 Pfizer - Will a Patent Cliff Be Avoided Following the Expiries of Sutent and Inlyta? 6.1.2 Novartis - How Will Upcoming Patent Expiries Affect Urological Cancer Revenues? 6.1.3 Johnson & Johnson - How Will Zytiga... Read more
2d
Swissinfo
Novartis boss keeps faith in new cancer treatmentsThe head of Swiss pharma giant, Novartis, Joe Jimenez, explains why he thinks t
Novartis boss keeps faith in new cancer treatments
Swissinfo / Posted 2 days ago
The head of Swiss pharma giant, Novartis, Joe Jimenez, explains why he thinks the company’s cancer drugs strategy will keep it on top. (SRF/swissinfo.ch) Since Jimenez became CEO in 2010, he has restructured Novartis, turning a loosely affiliated... Read more
3d
Roll Call
Aviation, Drug Pricing Keep Lobbyists Busy in Election Yearalso spent more on K Street this quarter, including Pfizer Inc.; AbbVie Inc.; G
Aviation, Drug Pricing Keep Lobbyists Busy in Election Year
Roll Call / Posted 3 days ago
also spent more on K Street this quarter, including Pfizer Inc.; AbbVie Inc.; Gilead Sciences Inc.; AstraZeneca PLC; Novartis International AG; and Merck & Co. Inc. Together, those companies spent more than $14.3 million in the first quarter,... Read more
3d
Business Wire
ImmunoGen, Inc. Announces Conference Call to Discuss Its Fourth Quarter and Fiscal Year 2016 Financial Resultsin three other clinical-stage ImmunoGen product candidates, and in programs in
ImmunoGen, Inc. Announces Conference Call to Discuss Its Fourth Quarter and Fiscal Year 2016 Financial Results
Business Wire / Posted 3 days ago
in three other clinical-stage ImmunoGen product candidates, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. Kadcyla® is a registered trademark of Genentech, a member of the Roche... Read more
3d
Swissinfo
Roche says UK faces losing lead in medical research after Brexitstruck an upbeat tone on the future of the pharmaceuticals sector in the United
Roche says UK faces losing lead in medical research after Brexit
Swissinfo / Posted 3 days ago
struck an upbeat tone on the future of the pharmaceuticals sector in the United States. Earlier this week, Swiss rival Novartis warned about an increasingly tough price environment following November's election with both Hillary Clinton and... Read more
3d
AllAfrica.com
NDA Warns of Counterfeit Malaria Drugs on Marketpublic and should not be on sale in any outlet," Mr Ssekyana warned. A stateme
NDA Warns of Counterfeit Malaria Drugs on Market
AllAfrica.com / Posted 3 days ago
public and should not be on sale in any outlet," Mr Ssekyana warned. A statement released by NDA yesterday indicated that Novartis Pharmaceuticals, the manufacturer of the genuine Coartem, through the local technical representative Surgipharm... Read more
4d
Swissinfo
Valeant Scores a Rare Win, But Hold the High-Fives: Gadflyan even bigger risk given how competitive this drug class is. Johnson & Johnson
Valeant Scores a Rare Win, But Hold the High-Fives: Gadfly
Swissinfo / Posted 4 days ago
an even bigger risk given how competitive this drug class is. Johnson & Johnson's Stelara is a $2.4 billion blockbuster. Novartis' Cosentyx was approved in early 2015. And Eli Lilly's Taltz, approved earlier this year, is potentially more... Read more
4d
Fortune
Inhaler Makers Want to Watch Every Breath You Takegovernments and insurers, though they need to tread carefully on data privacy.
Inhaler Makers Want to Watch Every Breath You Take
Fortune / Posted 4 days ago
governments and insurers, though they need to tread carefully on data privacy. GlaxoSmithKline gsk, AstraZeneca azncf, and Novartis nvs all are chasing the opportunity via deals with device firms including U.S.-based Propeller Health and... Read more
4d
Newsmax
Does the UN Understand the Value and Protections of Drug Patents?solutions if copycats were allowed to roam free unchecked? If unchecked, what
Does the UN Understand the Value and Protections of Drug Patents?
Newsmax / Posted 4 days ago
solutions if copycats were allowed to roam free unchecked? If unchecked, what would be the financial incentive for Novartis, Pfizer, Roche Holding, Sanofi US, Johnson & Johnson and dozens of other pharmaceutic companies to invest billions... Read more
4d
The Economic Times
One can't afford to stay fully invested in the market at this level: Pashupati Advani, Pashupati Advani@globalforaysusceptible but then again Sun is a big producer. As you mentioned about the dr
One can't afford to stay fully invested in the market at this level: Pashupati Advani, Pashupati Advani@globalforay
The Economic Times / Posted 4 days ago
susceptible but then again Sun is a big producer. As you mentioned about the drug, right now that they have got a parent. Novartis has actually got higher sales and they are in that space. So they will also presumably have higher sales. So all in... Read more
4d
Business Wire
PeptiDream Announces License of PDPS Technology to Genentechwith 15 of the leading pharmaceutical companies; Amgen, AstraZeneca, Bristol-My
PeptiDream Announces License of PDPS Technology to Genentech
Business Wire / Posted 4 days ago
with 15 of the leading pharmaceutical companies; Amgen, AstraZeneca, Bristol-Myers-Squibb, Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, Merck, Sanofi, Teijin, Kyorin, Ipsen, Genentech, Shionogi, and Asahi Kasei, all... Read more
5d
Pacific Coast Business Times
FDA declines to approve Novartis biosimilar for Amgen’s Neulastaversion of Amgen’s blockbuster drug Neulasta. Reuters reported July 19 that th
FDA declines to approve Novartis biosimilar for Amgen’s Neulasta
Pacific Coast Business Times / Posted 5 days ago
version of Amgen’s blockbuster drug Neulasta. Reuters reported July 19 that the FDA sent a letter to Swiss pharmaceutical Novartis at the end of June saying it was declining to approve the drug for now. Neulasta, made by Thousand Oaks-based... Read more
3 related stories
5d
Fortune
Amgen Finally Scores a Win In Its Big Copycat Drug Battle With NovartisShares of Novartisnvs remained relatively flat Tuesday as the company announced
Amgen Finally Scores a Win In Its Big Copycat Drug Battle With Novartis
Fortune / Posted 5 days ago
Shares of Novartisnvs remained relatively flat Tuesday as the company announced second-quarter earnings hadn’t fallen as much as expected. But in a blow, the Swiss pharma giant also revealed that regulators have rejected one of its experimental... Read more
3 related stories
5d
Zero Hedge
So What Did The ECB Buy? "In Short, Almost Everything"we made a few months ago that CSPP is really “QE for the world”. Plenty of Swis
So What Did The ECB Buy? "In Short, Almost Everything"
Zero Hedge / Posted 5 days ago
we made a few months ago that CSPP is really “QE for the world”. Plenty of Swiss credits have been bought (such as Nestle, Novartis and Adecco) as have UK credits (Unilever) and US credits (Schlumberger and Bunge). The ECB even dipped into... Read more
5d
Morningstar
Drug Group Lifts J&J; Shares Still Overvaluedcompetition increases and generics launch on complex older drugs. On the brande
Drug Group Lifts J&J; Shares Still Overvalued
Morningstar / Posted 5 days ago
competition increases and generics launch on complex older drugs. On the branded side, new competing immunology drugs (Novartis’ Cosentyx, Eli Lilly’s Taltz, and Takeda’s Entyvio) are likely to take market share from Johnson & Johnson's largest... Read more
5d
Reuters UK Edition
Novartis launches big pharma Q2 earnings The first of the big pharmas reveal Q2 earnings, with Novartis warning its pr
Novartis launches big pharma Q2 earnings
Reuters UK Edition / Posted 5 days ago
The first of the big pharmas reveal Q2 earnings, with Novartis warning its profits may decline as it spends more on marketing. As Hayley Platt reports, pharma has benefitted as a defensive sector post-Brexit... Read more
5d
AdWeek
Pharma Giant GSK Consolidates Its Global Agency Roster Across 4 Holding CompaniesIn 2015, GlaxoSmithKlein and Novartis completed a deal worth more than $20 bill
Pharma Giant GSK Consolidates Its Global Agency Roster Across 4 Holding Companies
AdWeek / Posted 5 days ago
In 2015, GlaxoSmithKlein and Novartis completed a deal worth more than $20 billion that combined the two companies' assets. In November of that year, various sources reported that the newly created company planned to launch a review of its agency... Read more
5d
The Economic Times
Novartis in no rush to sell down stake on GSK consumer ventureThere has been speculation that Novartis might look to try and sell its 36.5 pe
Novartis in no rush to sell down stake on GSK consumer venture
The Economic Times / Posted 5 days ago
There has been speculation that Novartis might look to try and sell its 36.5 percent holding before an agreed trigger date of 2018, but Joe Jimenez played down the idea in a post-results call with analysts on Tuesday. He noted the consumer business... Read more
5d
Connecticut Post
Novartis profit slips as generic drug competition hits salesFILE - This Oct. 25, 2011 file photo shows the logo of Swiss pharmaceutical com
Novartis profit slips as generic drug competition hits sales
Connecticut Post / Posted 5 days ago
FILE - This Oct. 25, 2011 file photo shows the logo of Swiss pharmaceutical company Novartis AG on one of their buildings in Basel, Switzerland. Swiss pharmaceuticals company Novartis says Tuesday July 19, 2016 a key measure of its profits fell 3... Read more
3 related stories
5d
Darien News-Review
Novartis profit slips as generic drug competition hits salesFILE - This Oct. 25, 2011 file photo shows the logo of Swiss pharmaceutical com
Novartis profit slips as generic drug competition hits sales
Darien News-Review / Posted 5 days ago
FILE - This Oct. 25, 2011 file photo shows the logo of Swiss pharmaceutical company Novartis AG on one of their buildings in Basel, Switzerland. Swiss pharmaceuticals company Novartis says Tuesday July 19, 2016 a key measure of its profits fell 3... Read more
3 related stories
5d
Reuters
Novartis in no rush to sell down stake on GSK consumer ventureA Novartis logo is pictured on its headquarters building in Mumbai April 1, 201
Novartis in no rush to sell down stake on GSK consumer venture
Reuters / Posted 5 days ago
A Novartis logo is pictured on its headquarters building in Mumbai April 1, 2013. Novartis (NOVN.S) is happy with the performance of its consumer health joint venture with GlaxoSmithKline (GSK.L), in which the Swiss drugmaker has a minority stake,... Read more
5d
Beaumont Enterprise
Novartis profit slips as generic drug competition hits salesFILE - This Oct. 25, 2011 file photo shows the logo of Swiss pharmaceutical com
Novartis profit slips as generic drug competition hits sales
Beaumont Enterprise / Posted 5 days ago
FILE - This Oct. 25, 2011 file photo shows the logo of Swiss pharmaceutical company Novartis AG on one of their buildings in Basel, Switzerland. Swiss pharmaceuticals company Novartis says Tuesday July 19, 2016 a key measure of its profits fell 3... Read more
3 related stories
5d
Stamford Advocate
Novartis profit slips as generic drug competition hits salesFILE - This Oct. 25, 2011 file photo shows the logo of Swiss pharmaceutical com
Novartis profit slips as generic drug competition hits sales
Stamford Advocate / Posted 5 days ago
FILE - This Oct. 25, 2011 file photo shows the logo of Swiss pharmaceutical company Novartis AG on one of their buildings in Basel, Switzerland. Swiss pharmaceuticals company Novartis says Tuesday July 19, 2016 a key measure of its profits fell 3... Read more
3 related stories
5d
CNBC
Early movers: GS, UNH, JNJ, NFLX, PM, CMG, IBM, YHOO, AMZN & morebe unveiled today. The lawsuits involve accusations of violating environmental
Early movers: GS, UNH, JNJ, NFLX, PM, CMG, IBM, YHOO, AMZN & more
CNBC / Posted 5 days ago
be unveiled today. The lawsuits involve accusations of violating environmental laws and allegedly defrauding regulators. Novartis — Novartis said full-year profit may decline due to increased marketing spending by the drugmaker for its new heart... Read more
5d
KELO Sioux Falls
Tuesday Morning Business Brief - July 19like monitoring systems that rarely fail and hardly ever require intervention.
Tuesday Morning Business Brief - July 19
KELO Sioux Falls / Posted 5 days ago
like monitoring systems that rarely fail and hardly ever require intervention. GENEVA (AP) - Swiss pharmaceuticals company Novartis says net profit from continuing operations fell 3 percent in the second quarter, largely because of new generic... Read more
5d
Swissinfo
Novartis Ramps Up Heart Drug Spending as Top Seller Goes Generic(Bloomberg) -- Novartis AG is ramping up marketing efforts for the heart drug E
Novartis Ramps Up Heart Drug Spending as Top Seller Goes Generic
Swissinfo / Posted 5 days ago
(Bloomberg) -- Novartis AG is ramping up marketing efforts for the heart drug Entresto, one of two new medicines essential to generating revenue as the company’s bestseller faces generic competition. The Swiss drugmaker will spend an additional $200... Read more
2 related stories
5d
DW
Pharma sector changes as generic market grows |major victory in India. The country highest court decided that Indian manufactu
Pharma sector changes as generic market grows |
DW / Posted 5 days ago
major victory in India. The country highest court decided that Indian manufacturers can continue making generic versions of Novartis' Gleevec, a drug that has been effective in treating some forms of leukemia. New markets for the pharmaceutical... Read more
5d
DW
Generic drug competition hits Novartis sales |Novartis said on Tuesday that its net income from continuing operations had fal
Generic drug competition hits Novartis sales |
DW / Posted 5 days ago
Novartis said on Tuesday that its net income from continuing operations had fallen by $50 million (45 million euros) from April to June this year because it was no longer the only company marketing a special cancer treatment, which it sells under the... Read more
9 related stories
5d
Herald Sun
Novartis 2Q net profit slipsSwiss pharmaceuticals company Novartis says net profit from continuing operatio
Novartis 2Q net profit slips
Herald Sun / Posted 5 days ago
Swiss pharmaceuticals company Novartis says net profit from continuing operations dropped 3 per cent in the second quarter, largely because of new generic competition for its top cancer drug. The Basel-based giant reported on Tuesday that net income... Read more
9 related stories
5d
The Economic Times
Novartis, world's top drugmaker, plays down Brexit threatstrongly in the UK despite the decision to exit the EU as we see very large are
Novartis, world's top drugmaker, plays down Brexit threat
The Economic Times / Posted 5 days ago
strongly in the UK despite the decision to exit the EU as we see very large areas of unmet medical need and the innovation Novartis brings can help patients in the UK." The sanguine comments from Jimenez, who is also president of the European... Read more
5d
Perth Now
Novartis 2Q net profit slipsSwiss pharmaceuticals company Novartis says net profit from continuing operatio
Novartis 2Q net profit slips
Perth Now / Posted 5 days ago
Swiss pharmaceuticals company Novartis says net profit from continuing operations dropped 3 per cent in the second quarter, largely because of new generic competition for its top cancer drug. The Basel-based giant reported on Tuesday that net income... Read more
9 related stories
5d
The Courier Mail
Novartis 2Q net profit slipsSwiss pharmaceuticals company Novartis says net profit from continuing operatio
Novartis 2Q net profit slips
The Courier Mail / Posted 5 days ago
Swiss pharmaceuticals company Novartis says net profit from continuing operations dropped 3 per cent in the second quarter, largely because of new generic competition for its top cancer drug. The Basel-based giant reported on Tuesday that net income... Read more
9 related stories
5d
RTE News
Novartis warns its 2016 profit may fallNovartis has warned that its profit may decline this year as it ramps up market
Novartis warns its 2016 profit may fall
RTE News / Posted 5 days ago
Novartis has warned that its profit may decline this year as it ramps up marketing spending on new heart failure drug Entresto after a disappointing start for the medicine. Combined with falling sales of leukaemia treatment Gleevec, core operating... Read more
9 related stories
5d
CTV News
Novartis 2Q net slips as generic drug competition hits salesGENEVA -- Swiss pharmaceuticals company Novartis says net profit from continuin
Novartis 2Q net slips as generic drug competition hits sales
CTV News / Posted 5 days ago
GENEVA -- Swiss pharmaceuticals company Novartis says net profit from continuing operations dropped 3 per cent in the second quarter, largely because of new generic competition for its top cancer drug. The Basel-based giant reported Tuesday that net... Read more
9 related stories
5d
The Irish Times
Novartis earnings dip as cancer drug faces generic competitionNovartis’s second-quarter earnings declined 3 per cent as the company grapples
Novartis earnings dip as cancer drug faces generic competition
The Irish Times / Posted 5 days ago
Novartis’s second-quarter earnings declined 3 per cent as the company grapples with tumbling sales of its cancer medicine Gleevec and invests in new products like heart drug Entresto and Cosentyx for psoriasis. Profit fell to $1.23 a share,... Read more
2 related stories
5d
Market Watch
Novartis warns on profit amid Entresto investmentSwiss pharmaceutical giant Novartis AG cautioned that its profit could fall thi
Novartis warns on profit amid Entresto investment
Market Watch / Posted 5 days ago
Swiss pharmaceutical giant Novartis AG cautioned that its profit could fall this year due to heavy investment in its new heart-failure drug Entresto, after reporting a drop in net profit in the second quarter due to currency headwinds. The company... Read more
9 related stories
5d
Salon.com
Novartis 2Q net slips as generic drug competition hits salesGENEVA (AP) — Swiss pharmaceuticals company Novartis says net profit from conti
Novartis 2Q net slips as generic drug competition hits sales
Salon.com / Posted 5 days ago
GENEVA (AP) — Swiss pharmaceuticals company Novartis says net profit from continuing operations dropped 3 percent in the second quarter, largely because of new generic competition for its top cancer drug. The Basel-based giant reported Tuesday that... Read more
9 related stories
5d
Island Packet
Novartis 2Q net slips as generic drug competition hits salesSwiss pharmaceuticals company Novartis says net profit from continuing operatio
Novartis 2Q net slips as generic drug competition hits sales
Island Packet / Posted 5 days ago
Swiss pharmaceuticals company Novartis says net profit from continuing operations dropped 3 percent in the second quarter, largely because of new generic competition for its top cancer drug. The Basel-based giant reported Tuesday that net income... Read more
9 related stories
5d
Daily Herald
Novartis 2Q net slips as generic drug competition hits salesGENEVA -- Swiss pharmaceuticals company Novartis says net profit from continuin
Novartis 2Q net slips as generic drug competition hits sales
Daily Herald / Posted 5 days ago
GENEVA -- Swiss pharmaceuticals company Novartis says net profit from continuing operations dropped 3 percent in the second quarter, largely because of new generic competition for its top cancer drug. The Basel-based giant reported Tuesday that net... Read more
9 related stories
5d
Swissinfo
Novartis Profit Declines as Competition Hurts Cancer Drug Sales(Bloomberg) -- Novartis AG’s second-quarter earnings declined 3 percent as the
Novartis Profit Declines as Competition Hurts Cancer Drug Sales
Swissinfo / Posted 5 days ago
(Bloomberg) -- Novartis AG’s second-quarter earnings declined 3 percent as the company grapples with tumbling sales of its cancer medicine Gleevec and invests in new products like heart drug Entresto and Cosentyx for psoriasis. Profit fell to $1.23... Read more
2 related stories
More

People in this news